Treatment of metastatic lipid cell tumor of the ovary with BV-CAP and VAC chemotherapy, using serum testosterone and dihydrotestosterone as tumor markers.
A metastatic ovarian lipid cell tumor was treated with BV-CAP chemotherapy following cytoreductive surgery and VAC chemotherapy for persistent disease found at second-look laparotomy before disease progression was noted. Serum Dihydrotestosterone (DHT) levels correlated with disease status during all phases of treatment, as did serum testosterone (T) to a lesser degree. Measurement of these two hormones may provide additional useful information on the response of patients with subclinical metastatic disease to post-operative therapy.
Patsner
B
B
Department of Obstetrics and Gynecology, School of Medicine, Sunny, Stony Brook, N.Y.
Piver
M S
MS
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D013196:Dihydrotestosterone / Q000097:blood*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008067:Lipoma / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*; D014750:Vincristine / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D013196:Dihydrotestosterone; D001761:Bleomycin; D003609:Dactinomycin; D013739:Testosterone; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin